Michael Chi, the Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On January 2, Chi sold 2,055 shares of Class A common stock at a price of $24.62 per share, amounting to $50,594. This transaction is part of a pre-established trading plan under Rule 10b5-1, which was adopted on March 1, 2024.

In addition, Chi exercised stock options to acquire 2,055 shares at a price of $11.53 per share, worth $23,694. After these transactions, Chi directly owns 193,601 shares of Hims & Hers Health. Stock options exercised are subject to a service-based vesting schedule, with 1/48th of the options vesting monthly beginning April 1, 2023.

In other recent news, Hims & Hers Health has made significant strides in the digital health sector. Needham & Company named Hims & Hers as their top pick for 2025, raising their price target on the company’s shares to $31. This adjustment highlights the company’s growth potential, with an emphasis on different ways for growth such as personal product adoption and an expansion of various weight loss solutions.

In addition, Hims & Hers Health reported a 77% year-over-year increase in sales in Q3, which exceeded $400 million, and predicted revenue in Q4 2024 between $465 million and $470 million. . However, the company’s shares fell sharply by 15% after the FDA’s resolution of the shortage of tirzepatide injection, which could change the dynamics of the market for obesity drugs.

On the other hand, Morgan Stanley (NYSE: ) initiated coverage of Hims & Hers Health with an Overweight rating, citing its strong performance in the digital health and direct-to-consumer sectors. Despite the potential volatility, the company suggests that the investment case has a favorable risk-reward profile. In addition, Hims & Hers Health announced a partnership with Eli Lilly (NYSE: ) to streamline access to the FDA-approved drug Zepbound.

These developments highlight Hims & Hers Health’s commitment to growth and innovation in the digital health sector. However, the company’s future also depends on the potential relationship with the FDA leadership and the agency’s stance on compounding GLP-1 products.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.